ÂÜÀòÂÒÂ×

Katja Rosenkranz is a seasoned professional in the life sciences sector, currently serving as a Partner and Principal at V-Bio Ventures since May 2016. Rosenkranz holds board positions at ExeVir, dualyx, and AgomAb Therapeutics, showcasing a strong leadership role in various organizations since 2020. Previously, Rosenkranz was the Interim CEO of AgomAb Therapeutics from February 2018 to April 2019 and has extensive experience in investment and project management as a Senior Investment and Project Manager at Ascenion GmbH from 2011 to 2016. Earlier roles include Managing Director at Dr. Katja Rosenkranz & Rainer Friedl Gbr and CBO/CFO at Hepa Wash, where responsibilities ranged from strategic development to fundraising. An educational background includes a PhD in Biochemistry from the University Witten/Herdecke and the Max Planck Institute of Neurobiology, along with an Executive MBA in Medical Devices & Healthcare Management.